Lung Biopsy Systems Market size was valued at USD 3.46 Billion in 2023 and is set to reach USD 22.28 Billion by the end of 2036, expanding at around 15.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of lung biopsy systems is assessed at USD 3.94 Billion. The reason behind the growth is impelled by a higher prevalence of lung cancer across the globe. As a result, there is a greater need for timely diagnosis which necessitates the use of a lung biopsy system. By extracting samples of lung tissue that may be utilized for molecular testing, a lung biopsy is a generally acknowledged method for identifying pulmonary illnesses. A report published by World Health Organization (WHO) stated that in 2020, around 10 million people died due to lung cancer which was summed up to be 1 in 6 deaths worldwide.
The growing inclination toward minimally invasive surgeries is believed to fuel lung biopsy systems market growth. Minimally invasive surgeries come under the ongoing advancement of the medtech industry and it is performed by delivering less damage to the body with the assistance of enhanced medical imaging equipment services.
Moreover, the use of a robotic-assisted system in minimally invasive lung biopsy enables medical professionals performing the procedure to access all 18 lung regions, enabling the best lung navigation and producing more precise biopsies. This type of treatment is safe, effective, and minimally invasive, which can reduce discomfort, recovery time, and infection risk.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
15.4% |
|
Base Year Market Size (2023) |
USD 3.46 Billion |
|
Forecast Year Market Size (2036) |
USD 22.28 Billion |
|
Regional Scope |
|
Procedure Type (Transbronchial, Thoracoscopic, Open Biopsy)
The open biopsy segment is estimated to hold 68% share of the global lung biopsy systems market in the coming years owing to the higher number of patients receiving it. Open lung biopsy is the most common type of biopsy that is performed to check for the sigh of diseases in the lungs. It is tolerably risk-free and generally regarded as the most reliable biopsy technique. Hospitals use general anesthesia to perform open lung biopsies, where during the entire operation, patients are asleep and don't feel any pain.
End-User (Cancer Research Centers, Specialty Clinics, Hospitals)
Lung biopsy systems market from the hospitals segment is set to garner a notable share in the near future owing to an increasing number of hospitals. This offers patients with better access to healthcare services which can result in a huge number of lung biopsies being performed. For instance, patients now have a new, minimally invasive lung biopsy option available from the hospital which offers the technology and medical know-how to retrieve lung biopsy tissue samples from the deepest parts of the lung, to improve the chances of lung disease diagnosis and treatment. Besides this, hospitals provide round-the-clock services to patients and are equipped with advanced medical equipment. Medical professionals who have expertise in lung biopsy systems are also easily available within hospital premises.
Our in-depth analysis of the global lung biopsy systems market includes the following segments:
|
Product Type |
|
|
Procedure Type |
|
|
End Use |
|
North American Market Forecast
Lung biopsy systems market in North America is predicted to account for the largest share of 42% by the end of 2036 impelled by growing research and clinical trials to test a new approach to treatment for lung cancer. Therefore, to support these efforts the demand for lung biopsy systems is expected to rise in the region. According to statistics, in 2021, North America saw over 25% global increase in clinical drug trial initiations.
APAC Market Statistics
The Asia Pacific lung biopsy systems market is estimated to be the second largest, during the forecast timeframe led by growing air pollution in the environment owing to the rapid urbanization and industrialization in the region. For instance, the deteriorating air pollution in India is being attributed by medical professionals to a rapid increase in cases of chest and throat sickness, and many respiratory ailments. This has led to increasing demand for lung biopsy systems in the region. India, a fast-developing nation with a growing population, suffers from severe air pollution, and it is estimated that more than 25,000 people die from it every year in Delhi.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?